IASLC 2021

Pretreatment ctDNA Predicts Survival in Non-Small Cell Lung Cancer

PD-L1 expression and tumor mutational burden were not associated with survival.

Global Impact of COVID-19 on Enrollment in Lung Cancer Trials

Enrollment declined 43% from 2019 to 2020.

Socioeconomic Status Does Not Predict Survival in Mesothelioma

Factors associated with poor survival were advanced age and male sex.

Lurbinectedin Plus Doxorubicin Improves PFS, Not OS, in Small-Cell Lung Cancer

The 12-month progression-free survival rate was superior in the lurbinectedin arm.

Adding Immunotherapy to Chemo Improves Survival in Metastatic Non-Small Cell Lung Cancer

The combinations conferred benefits in nonsquamous non-small cell lung cancer only.

Study Reveals Shorter Time to Lung Cancer Treatment During COVID-19 Pandemic

The time from cytohistological diagnosis to treatment initiation was longer in 2019 than in 2020.

Lung Cancer Patients Have Lower Antibody Response to COVID-19 Vaccination

Researchers are evaluating whether specific anticancer therapies affect antibody levels.

Type of Surgery and Surgical Pathway Tied to Risk of Perioperative COVID-19 in Non-Small Cell Lung Cancer

Perioperative COVID-19 was associated with a 30-day mortality rate of 26%.